(thirdQuint)Study of Fluzone Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults.

 Historically, the annual safety and immunogenicity study of Fluzone vaccine has been conducted in the US in support of licenses held by sanofi pasteur in various countries.

 Participants will be randomized to receive a dose of either Fluzone(R) or Fluzone(R) High-Dose vaccine and will be followed up for safety and immunogenicity.

 The duration of participation in the trial will be approximately 1 month.

.

 Study of Fluzone Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults@highlight

The aim of the study is to evaluate the safety and immunogenicity of the 2011-2012 formulation of Fluzone and Fluzone High-Dose vaccines in participants aged 65 years and older.

 Objectives: - To describe the safety of Fluzone vaccine and Fluzone High-Dose vaccine among adults 65 years of age.

 - To describe the immunogenicity of Fluzone vaccine and Fluzone High-Dose vaccine among adults 65 years of age.

